title: (+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
authors.forename: F J
authors.initials: FJ
authors.lastname: Grandas Perez
authors.forename: P G
authors.initials: PG
authors.lastname: Jenner
authors.forename: M
authors.initials: M
authors.lastname: Nomoto
authors.forename: S
authors.initials: S
authors.lastname: Stahl
authors.forename: N P
authors.initials: NP
authors.lastname: Quinn
authors.forename: J D
authors.initials: JD
authors.lastname: Parkes
authors.forename: P
authors.initials: P
authors.lastname: Critchley
authors.forename: C D
authors.initials: CD
authors.lastname: Marsden
mesh_terms: D000818:Animals; D002144:Callithrix; D002230:Carbidopa / Q000008:administration & dosage; D004294:Domperidone / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
chemical_list: C043445:4-propyl-7-hydroxy-1,2,3,4a,5,6-hexahydronaphthoxazine; D004338:Drug Combinations; D010078:Oxazines; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D004294:Domperidone; D002230:Carbidopa